相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab
Heinz Wiendl et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)
Severe fingolimod rebound syndrome after switching to cladribine treatment
Fernanda Coss-Rovirosa et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Long-term peripheral immune cell profiling reveals further targets of oral cladribine in MS
Tobias Moser et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2020)
Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers
Olaf Stuve et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2019)
Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells
Bryan Ceronie et al.
JOURNAL OF NEUROLOGY (2018)
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Alan J. Thompson et al.
LANCET NEUROLOGY (2018)
Cladribine Tablets: A Review in Relapsing MS
Emma D. Deeks
CNS DRUGS (2018)
Immunological correlates of mycobacterial growth inhibition describe a spectrum of tuberculosis infection
Matthew K. O'Shea et al.
SCIENTIFIC REPORTS (2018)
Both cladribine and alemtuzumab may effect MS via B-cell depletion
David Baker et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2017)
An observational study of alemtuzumab following fingolimod for multiple sclerosis
Mark Willis et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2017)
Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment
Stacy Ellen Hatcher et al.
JAMA NEUROLOGY (2016)
Dysregulation of sphingosine 1 phosphate receptor-1 (S1P1) signaling and regulatory lymphocyte-dependent immunosuppression in a model of post-fingorimod MS rebound
Leonardo Cavone et al.
BRAIN BEHAVIOR AND IMMUNITY (2015)
Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial
Thomas P. Leist et al.
LANCET NEUROLOGY (2014)
Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients
Trina A. Johnson et al.
CLINICAL IMMUNOLOGY (2010)
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
Gavin Giovannoni et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
分享论文
